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Abstract
OBJECTIVES— Develop a fully automated, objective method for evaluating morphology on breast
MR and evaluate effectiveness of the new morphological method for detecting breast cancers.
SUBJECTS AND METHODS— We present a new automated method (Morphological Blooming)
for identifying and classifying breast lesions on MR which measures margin sharpness, a
characteristic related to blooming, defined as rapid enhancement, with a border that is initially sharp
but becomes unsharp after seven minutes. Independent training sets (98 biopsy-proven lesions) and
testing sets (179 breasts, 127 patients, acquired at 5 institutions) were used. Morphological Blooming
was evaluated as a stand-alone feature and as an adjunct to kinetics using FROC (free-response ROC)
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and sensitivity analysis. Dependence of false positive (FP) rates on acquisition times and pathologies
of contralateral breasts were evaluated.
RESULTS— Sensitivity of Morphological Blooming was 80% with 2.46 false positives (FP) per
non-cancerous breast: FPs did not vary significantly by acquisition times. FPs varied significantly
by pathologies of contralateral breasts (cancerous contralateral: 4.29 FP/breast; non-cancerous
contralateral: 0.48 FP/breast; p<.0001). Evaluation of 45 cancers showed suspicious morphologies
on 10/15 (67%) cancers with benign-like kinetics and suspicious kinetics on 5/10 (50%) cancers with
benign-like morphologies.
CONCLUSION— We present a new, fully automated method of identifying and classifying margin
sharpness of breast lesions on MR that can be used to direct radiologists’ attention to lesions with
suspicious morphologies. Morphological Blooming may have important utility for assisting
radiologists in identifying cancers with benign-like kinetics and discriminating normal tissues that
exhibit cancer-like enhancement curves and for improving the performance of CAD systems.
Studies have demonstrated the effectiveness of breast MRI for improving breast cancer
detection and diagnosis [1,2,3,4,5,6,7]. Breast MRI presents the breast imager with two
challenges: low specificity, which can result in a clinically unacceptable number of false
positives [8,9], and a large number of images that must be interpreted. Recent screening studies
in Netherlands, Canada, and United Kingdom have reported breast cancer sensitivities using
MRI ranging from 71%–77% [3]. A follow-up of the MARIBS study in the United Kingdom
found that independent double-reading of breast MRI improved sensitivity by 7% [10]. To
address these challenges, breast MRI computer-aided-detection (CAD) systems have been
developed to help radiologists more easily sort through images and focus on suspicious areas
of enhancement to improve efficiencies in interpreting breast MRI.
Interpretive features that are used to discriminate malignant from benign lesions on breast MRI
fall into two general categories: kinetics, based on the rate and degree an enhancing agent
washes into and out of a region-of-interest, and morphology, based on the shape and texture
of the enhancement pattern [11]. Some cancers, particularly invasive lobular [7,12], DCIS
[12,13,14], and scirrhous ductal invasive cancers [7], often fail to exhibit cancer-like kinetics.
Moreover, some benign conditions, such as fibroadenomas and hyperplasia produce dynamic
patterns similar to malignancies [15]. The American College of Radiology recommends that
radiologists evaluate both kinetic and morphologic characteristics [16].
Commercialized breast MRI CAD systems have relied primarily on kinetic analysis for
detecting suspicious regions [17]. While there has been research in computer analysis of
morphology [18,19,20], clinical assessment still relies on reader interpretation to evaluate
morphology [4,21]. Studies on morphological measures for breast MRI have evaluated shape,
texture, orientation, intensity, gradients, and other factors that model tissues in the breast [18,
22,23,24]. None of the previously reported morphological measures has been shown to be
sufficiently robust, effective, and computationally efficient to be included in a commercialized
breast MRI CAD system. There is a clinical need for including morphological analysis into
CAD systems to assist radiologists in the detection of cancers and differentiation of benign
from malignant lesions [17].
Another serious and challenging problem is observer variability in evaluation of lesion
morphology. Mussurakis, et al. reported kappa statistics between pairs of radiologists who
interpreted contours (defined as: (a) well-defined, (b) partially well-defined, (c) irregular,
spiculated, or (d) irregular, nonspecific) on T1 weighted post-contrast breast MRI images as
0.34, 0.23, 0.34 [25]. Kinkel, et al. found an interobserver variability for margins (dichotomous
selection of: (a) smooth or unable to assess, and (b) irregular or spiculated) of 0.29 [26]. Kappa
statistics in the range 0.21–0.40 are considered to be “fair” agreement [27]. These results
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indicate a need to develop methods to decrease the variability of breast MRI interpretation.
Fully automated computer-generated features have no user variability and offer a means for
addressing this issue.
This paper presents analysis of a new objective method of identifying and classifying MRI
breast lesions on the basis of margin sharpness that is substantially different from the
morphological methods that have been reported previously. The method is fully automated and
can be used to direct the radiologist’s attention to lesions that have suspicious morphologies.
The new method may be particularly helpful for identifying cancers that lack suspicious kinetic
patterns. Prior studies have used subjective interpretations of margin characterization and
blooming, and such interpretations are dependent upon the experience of the radiologist. [28,
29]. The new feature presented here is generated by the computer without user input, which
increases objectivity and reproducibility, and simplifies MR analysis.
Subjects and Methods
Data
Independent data sets were used for the training and testing of the Morphological Blooming
feature. All images were T1-weighted, fat suppressed, and acquired on 1.5T MRI systems with
dedicated breast coils. For cases containing biopsied lesions, a site principal investigator (P.I.)
at the acquiring institution identified the location of the lesions that were biopsied and provided
the pathologic diagnoses. At each institution, IRB approval or exemption from review was
obtained. Data for training cases consisted of binary files containing intensity levels of pre-
and post-contrast T1 images and a summary statement of the protocol used to acquire the
images. Data for testing cases consisted of DICOM-compliant files that contained both image
and protocol data. For the testing cases, times of acquisition were estimated from the DICOM
header by subtracting the recorded time of the last pre-contrast image from the recorded time
of the post-contrast image. The following definitions are used: “normal” is a breast where no
lesion was found; “benign” is a breast with a biopsy-proven benign lesion and no indication
of cancer; “non-cancerous” is either normal or benign; “non-cancerous, contralateral to cancer”
is normal or benign with known cancer in the other breast; “non-cancerous, contralateral to
non-cancerous” is normal or benign with no cancer in the other breast; “non-cancerous,
contralateral to unknown” is normal or benign with no information about the other breast. A
breast is called “cancer” if it contains a biopsy-proven cancerous lesion.
Analysis of false positives (FP) was based exclusively on benigns and normals. Although FPs
can occur in breasts with known cancers, they are ignored in the FP analysis since we had
insufficient biopsy information to determine the location and extent of cancers throughout the
breast.
Data set used for training Morphological Blooming feature
Training of the feature was performed using two-dimensional images of biopsy-proven focal
masses. The training data set consisted of 98 cases (43 Benign; 55 Cancer) acquired using a
three-dimensional fat-suppressed, radiofrequency, spoiled gradient-echo sequence on a 1.5T
system with a Signa console (GE Medical Systems). The first post-contrast images were
obtained during the first 90 seconds after the delivery of a 20-mL bolus of a gadolinium-based
contrast agent, gadopentetate dimeglumine (Magnevist: Berlex, Wayne, NJ). The scan was
initiated after gadolinium injection but prior to a 20ml saline flush. Subsequent images of the
breast were taken immediately following the first post-contrast image. The resulting sagittal
images consist of 512x512 pixels and were obtained from an acquisition matrix of 512x256x32.
Field of view ranged from 16 to 22 cm, and slice thicknesses ranged from 1.5 to 4.0 mm,
depending on the size of the breast. Flip angle was ≤45.
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Data set used for testing Morphological Blooming feature
Only images of non-cancerous breasts (benigns and normals) and breasts with biopsy-proven
cancers were used. Since a true positive finding was recorded only when the location of a
biopsy-proven cancer was marked, breasts that were assessed as being cancer but where biopsy
results were not available were excluded from the study. Breasts in the testing set included
cancers (71), normals (53), and benigns (55) from 127 patients. Of the cancers, 37 were
infiltrating ductal, 6 infiltrating lobular, 4 infiltrating mixed ductal and lobular, 17 DCIS, 1
medullary, 6 unspecified. Of the normals, 28 were contralateral to cancer, 8 contralateral to
normal, 17 contralateral to benign. Of the benigns, 17 were contralateral to normal, 10
contralateral to benign, and 28 contralateral to unknown. 35 non-cancerous breasts had follow-
ups of at least 12 months and 4 had follow-ups 6–12 months; the remaining 69 non-cancerous
breasts were assessed on the basis of radiologists’ interpretations of images taken at the time
of, or within 6 months of, the original MR study. Four patients had multiple biopsy-proven
malignant lesions (three patients with two malignant lesions in one breast and none in the other
breast; one patient with two malignant lesions in one breast and one malignant lesion in the
other breast). The average age of patients was 48.4 years, with standard deviation 9.4 years.
Institutional protocols and data are summarized in Table 1.
Images in the testing set were obtained from five institutions using a variety of clinical and
research protocols which differed from the fixed protocol used for the training set. Protocol
values listed in Table 1 for time delay after contrast, echo times, flip angles, slice thicknesses,
and field-of-view (FOV) were obtained from DICOM headers for cases used in the study. For
institutions 3, 4 and 5, long time delays between pre-contrast image and post-contrast image
shown in Table 1 were due to intervening imaging of the contralateral breast after the contrast
injection and before imaging of the breast used in the study. For institution 2, long delays shown
in Table 1 were due to use of the third post-contrast image in the analysis, as recommended by
the site Principal Investigator, to account for slow uptake of the contrast agent resulting from
the lack of a saline push after injection.
Feature Overview
The lesion morphology characterization presented here is an assessment of the unsharpness of
borders using the pre-contrast and a single post-contrast T1 image. The feature is related to
blooming, a kinetic feature based on the physiological phenomenon of leakage from the core
of the lesion to surrounding tissue due to vascularization of the lesion [29,30]. Since malignant
lesions generally have greater vascularization than benign lesions, there is a greater kinetic
blooming effect. Fischer, et al showed that malignant breast lesions exhibit greater kinetic
blooming than benign lesions when evaluated over a seven minute time period [29].
Definition of Two-Dimensional Morphological Blooming Feature
All images were resized to 256x256 for processing. A feature value (MB-2D) based on the
magnitude of blooming was computed independently on each two-dimensional slice for each
cluster of enhancing pixels on the subtraction image using the following algorithm: (1) For
each enhancing region, a high-intensity threshold was determined to be the highest intensity
level that generated a cluster on the binary thresholded image exceeding 25 mm2 (the initial
cluster); (2) A nested sequence of clusters was generated from the initial cluster by successively
lowering the intensity level used for binary thresholding. The process was terminated when
the threshold reached the level of background tissue and the cluster expanded to include a large
portion of the breast; (3) A minimal bounding box was derived for each cluster in the nested
sequence. The bounding box served as a filter that reduced the effect of noise that distinguished
clusters in the nested sequence; (4) A segmented enhancement was defined to be the cluster
from the nested sequence of clusters that had the highest gradient and that exceeded 50 mm2
in size. The number of distinct bounding boxes was computed and used as the feature value
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for this segmented enhancement. For all cases in which a saline push was used after bolus
injection, the MB-2D feature was evaluated on the first post-contrast image. For cases from
Institution 2 for which a saline push was not used, the third post-contrast image was used.
If the lesion exhibited blooming, there was an unsharpness of the border, resulting in a large
number of distinct nested boxes (high MB-2D); if the lesion did not exhibit blooming, the
borders were sharp and a small number of distinct nested boxes were present (low MB-2D).
Analysis of training data suggested the following additional filters to help eliminate artifacts
and vessels: (1) Enhancement of at least 75% over pre-contrast image. This parameter setting
is comparable to enhancement thresholds suggested in the literature [29,31], and (2)
Compactness parameter (p2/A), where p is the perimeter and A the area of the lesion, [32] must
be less than or equal to 124, a value heuristically determined from the image data.
Definition of Three-Dimensional Morphological Blooming Feature
The MB-3D feature was formed by stacking overlapping adjacent two-dimensional enhancing
regions. The stacking operation resulted in a three-dimensional enhancement that was assigned
a feature values as follows: (1) For each slice in the three-dimensional enhancement, a
smoothed MB-2D value was derived by weighting the MB-2D within the given slice with a
factor of .5 and weighting the MB-2D values for enhancements in the adjacent slices with a
factor of .25; (2) the maximum smoothed MB-2D value over the set of slices in the three-
dimensional enhancement was used as the MB-3D feature value.
Evaluation Methodology
Performance of the Morphological Blooming feature as a sole discriminator of benign from
malignant conditions was evaluated using FROC (free-response ROC) analysis which
evaluates the true positive fraction (sensitivity) as a function of the number of false positives
(FPs) [33]. FROC evaluation is presented as an empirical plot of data obtained from the study,
without the use of model-fitting or smoothing. Sensitivity values were computed using breasts,
rather than patients, as the unit being scored; for the four breasts that contained two biopsied
malignant lesions, a marking on either of the lesions counted as a positive finding; for the one
patient that had biopsied malignant lesions in both breasts, the two breasts were analyzed and
scored independently. Similarly, FP values were computed independently for the left and right
breasts in those cases that were non-cancerous in both breasts.
Definition of True Positive (TP)—For each cancer, the site P.I. selected a spatial slice that
cut through the biopsied lesion and drew a two-dimensional box around the lesion on the
selected slice. An expert (RB) reviewed three-dimensional image sets of cancers, and, using
the two-dimensional boxes as guides, constructed three-dimensional cubes around the cancers.
For each cancer, the highest MB-3D value from the set of three-dimensional enhancements
that overlapped the expert’s cube by a minimum of 200 mm3 was evaluated and used in the
FROC analysis.
Definition of False Positives (FP)—A three-dimensional enhancement on a non-
cancerous breast was a false positive if the MB-3D value for that enhancement exceeded the
threshold criteria used in the FROC analysis and if a minimum of 200 mm3 of the enhancement
was on the breast side of the chest wall (ST).
Performance of the Morphological Blooming feature as an adjunct to kinetics was evaluated
using reader interpretations of kinetics from a prior reader study [34,35]. Readers were asked
to interpret lesion kinetics as persistent, plateau, or washout; interpretations of “persistent”
were assigned a score of 0, “plateau” a score of 1, and “washout” a score of 2. Overall reader
interpretation of kinetics for each case was evaluated using the median score. Benign lesions
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typically show persistent signal intensity curves while cancers more often show washout
[36]. Cancer cases that had median reader interpretations of 0 or .5 were used in the current
study as examples of cancer cases with benign-like kinetics.
Readers involved in this study were radiologists with varied experience in interpretation of
breast MRI. A total of 35 radiologists participated, of which 3 had no experience in breast MRI
interpretation, 11 had interpreted between 1 and 9 cases prior to participation in the study, 12
reported interpreting between 10 and 100 cases, and 9 reported interpreting greater than 100
cases. There was 1 radiology resident, 9 fellows in breast imaging, 17 attending radiologists
and 8 site principle investigators. Fields of expertise self-reported by the radiologists included
Neuroradiology (1), Nuclear (2), Ultrasound (1), Muscular-Skeletal (1), Interventional (2),
Abdominal (1), Body Imaging (4), General MRI (3), Mammography-Breast-Women’s
Imaging (24). Radiologists were allowed to identify more than one area of expertise.
Results
FROC analysis
Fig. 1 is the empirical FROC curve showing sensitivity as a function of number of false
positives (FP), using classification based solely on the three-dimensional Morphological
Blooming feature. The numbers 9 through 12 above the markers are the thresholds for the
Morphological Blooming feature used to compute the sensitivity and FP values. As an example,
sensitivity and FP values at the marker pointed to by the arrow were computed by calling
enhancements “cancer” if they had blooming values greater than or equal to 10 and calling
them “benign” if they had blooming values less than 10. Higher thresholds resulted in fewer
enhancements being called “cancer,” leading to lower sensitivities and lower FP rates.
Analysis of False Positives (FP)
Fig. 2 shows details of the distribution of FPs at threshold 10 for the 108 non-cancerous breasts.
The left bar shows that 37% of the cases had no FPs, or equivalently, for 37% of the cases, all
enhancements had Morphological Blooming values less than 10. The dark bar, second from
left, marks the median number of FPs.
Non-cancerous breasts averaged 0.47 FPs on 43 breasts from Institution 1 and 4.44 FPs on 43
breasts from Institution 4; difference in FP rates were statistically significant (p<.0001). The
numbers of non-cancerous breasts from other institutions were insufficient for statistical
analysis. Dependences of FP rates on two characteristics of the data sets were analyzed: (1)
acquisition times of first post-contrast images (Institution 1: mean 220 seconds; Institution 4:
mean 374 seconds; time difference was statistically significant (p<.0001)), and (2) pathologies
of patient populations (Institution 1: non-cancerous contralaterals (38), cancerous
contralaterals (5); Institution 4: non-cancerous contralaterals (4), cancerous contralaterals (25),
unknown contralaterals (14)).
Analysis of FP rate vs. acquisition time
FP rates were computed for all series of post-contrast images with means less than 600 seconds
from Institutions 1 and 4 (Institution 1: first, second, third post-contrast series; Institution 4:
first post-contrast series.). Results are shown in Fig. 3. There was no statistically significant
difference in FP rates among the three post-contrast series from Institution 1. All 3 post-contrast
series from Institution 1 had statistically significantly lower FP rates than were found on the
first post-contrast series for Institution 4 (p<.0001).
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Analysis of FP rate vs. pathologies of contralateral breasts
FP rates on non-cancerous breasts were computed independently for patients with cancerous
contralateral breasts and for patients with non-cancerous contralateral breasts. Results are
shown in Table 2.
Morphological Blooming and kinetic interpretation as complementary detection methods
Analysis of combined morphological and kinetic detection was performed on 45 breasts that
met the following three conditions: (1) the breast contained a biopsy-proven malignant lesion;
(2) multiple readers had interpreted kinetics at the lesion; (3) MR images of the full breast were
available for computer analysis. Cases in this set were interpreted by an average of 13.4
radiologists (Min=5; Max=18). The last row of Table 3 shows that 10 of 15 (67%) of cancers
with benign-like kinetics were identified as having suspicious margins, and 5 of 10 (50%) of
cancers with benign-like margins were interpreted as having suspicious kinetics.
Examples
Cases that demonstrate the utility of Morphological Blooming as a diagnostic criterion are
shown in Figures 4–5. Images show representative slices through the lesions on the first post-
contrast image after injection. Figures 4A and 5A show the original MR images; Figures 4B
and 5B show Morphological Blooming maps where red indicates Morphological Blooming
values greater than or equal to 10 (positive findings) and yellow indicates Morphological
Blooming values equal to 8–9 (near-positive findings); Figures 4C and 5C show kinetic maps,
where red indicates pixels with washout and yellow indicates pixels with plateau. Colorization
for Morphological Blooming is applied over the entire segmented lesion, rather than only the
border, to help radiologists easily detect suspicious regions.
Discussion
We present a new objective method of identifying areas with suspicious morphology on T1
weighted MR images of the breast. This new method evaluates unsharpness of margin on the
post-contrast image nearest to peak enhancement and is believed to be related to blooming,
defined as change in border sharpness between 1 and 7 minutes. The hypothesis that guided
our development of the new feature is that peripheral enhancement seen at seven minutes can
also be seen as a low-level enhancement on an earlier image since leakage from the core of the
lesion to the surrounding tissue occurs gradually over time. Since the new feature characterizes
margin sharpness, which is classified as a component of morphology in the BI-RAD lexicon,
we refer to the new feature as Morphological Blooming.
Morphological Blooming offers two advantages over reader assessment of blooming based on
early and late post-contrast images: (1) since Morphological Blooming is objectively measured,
there is no inter-observer variability. (2) Using a single post-contrast image at peak
enhancement reduces the impact of patient movement.
We have found Morphological Blooming to be effective at identifying and discriminating
breast cancers using a variety of different MRI protocols and systems. One important difference
among the protocols used in this study is the time of acquisition of the post-contrast images.
Acquisition times varied from 115 seconds to 1713 seconds, with the larger numbers
corresponding to cases in which the contralateral breast was imaged after the ipsilateral breast
was completely imaged. In spite of our efforts to use different protocols, there are still clinical
protocols not represented in our study. For example, our primary plane of acquisition was
always sagittal with fat suppression and minimal in-plane resolution of 1 mm. It is not known
if use of axial or coronal planes of acquisitions, non fat-suppressed images, or lower in-plane
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resolution will affect the accuracy of the Morphological Blooming feature. Further studies are
needed to validate our results for these different protocols.
Much of the data was obtained from cases acquired in prior diagnostic breast MR studies and
is likely not representative of cases found in a screening environment. Differences between
cases used in this study and cases found in clinical screening include: 1) 55 of 108 (51%) of
the study cancer-free breasts contained suspicious benign lesions. Thus the cancer-free breasts
contained a disproportionate number of hard-to-diagnose lesions; 2) Prevalence of cancer in
the study data was 40%, which is significantly higher than is found in a clinical screening
environment. 3) Average age of patients, 48.4, was comparable to other studies of symptomatic
women [10], but considerably higher than the average ages of 40–41 reported in large, multi-
center screening studies [1,3].
It has been reported that breast MRI has sensitivity approaching 100% for invasive cancers
and the primary need for computer support is to improve specificity. Three recent studies of
breast MRI have shown that sensitivity for high-risk screening is much lower, with reported
values of 71–77%. Accordingly, there may be an important role for CAD in improving
sensitivity in the high-risk screening environment. Since many breast MRI CAD systems rely
on kinetics to identify suspicious areas, there may be an important role for a breast MRI CAD
system that also evaluates morphology. One of the more important finding of this study was
that Morphological Blooming has the potential for complementing kinetics in identifying
suspicious areas. We identified 15 cancers that had benign-like kinetics and found that
Morphological Blooming marked 10 of these as being suspicious. Conversely, 5 of the 10
cancers that were missed using Morphological Blooming were interpreted as having suspicious
kinetics. In this limited study, a combination of Morphological Blooming and kinetic
interpretation achieved a sensitivity of 89%. While the set of cases in this analysis was small,
it shows the promise of Morphological Blooming as an important adjunct to kinetics in
identifying breast cancers. Additional research is needed in this area to both validate the results
on a larger set of cases.
Each of two institutions provided images for 40% of the non-cancerous breasts used in this
study. The highly significant difference in FP rates between these two institutions prompted
an analysis to try to identify the source of this difference. The institution with the larger FP
rate acquired much of its data in a study in which non-cancerous breasts were predominantly
contralateral to, and imaged subsequent to, breasts with known malignancies. The institution
with the smaller FP rate imaged patients in which both breasts were predominantly cancer-free
and generated these images using an interleaved sequence in which both breasts were imaged
within four minutes after injection of the contrast agent. Thus we hypothesized that two possible
sources of this difference were acquisition time and patient bias. Our analysis of images from
a single institution showed there was not significant relationship between acquisition time and
FP rates; this result suggests that the observed difference in FP rates between these two
institutions may be due, in part, to factors other than acquisition time. Since acquisition times
were estimated from DICOM header data, these estimations may have introduced errors which
affected our results. A second quantifiable difference between the two sets of images was
overall patient pathology. This analysis led to the intriguing finding that most of the false
positives were found in breasts that were contralateral to breasts with cancer. Since
synchronous contralateral breast cancer occurs in up to 6% of patients [36], it is possible that
the number of false positives could be related to risk. Additional research is required to
understand clinical importance of this observation.
The study was originally undertaken to develop methods of distinguishing between biopsy-
proven malignant lesions and biopsy-proven benign lesions. Accordingly, the study protocol
only required pathologies for specific lesions. It was only after we realized the potential of
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using some of the methodologies for detecting cancer that we started investigating the whole
breast and required assessment of whether the breast was normal or not. For some of the cases,
there was known follow-up data, leading to a verifiable assessment of non-cancerous; for other
cases, however, the assessment was made strictly on the basis of image interpretations from
the original MR study. The lack of standard for what constitutes a non-cancerous breast is a
major deficiency of this study.
The preliminary study results presented here show that Morphological Blooming may have
important utility for assisting radiologists in identifying cancers that do not exhibit cancer-like
washin-washout characteristics and in discriminating normal tissues that exhibit kinetic time
curves similar to malignancies.
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FROC curve for Morphological Blooming Feature. Arrow shows operating point
corresponding to threshold 10, with sensitivity=80% and 2.46 FP/Breast.
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Distribution of FP levels at threshold 10. Dark bar is at median number of FPs.
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False positive (FP) rates as a function of acquisition times. Solid markers show mean FP rates
from Institution 1 for first 3 postcontrast series. Open square shows mean FP rate for Institution
4 for first postcontrast series. Horizontal lines show ± 1 standard error.
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Fig 4. A 51-year-old female imaged on GE LX system. Patient had three areas identified on magnetic
resonance as suspicious. All three were found to be infiltrating lobular carcinoma on final
pathology. Only the subareolar mass was noted on mammography. Although all three regions with
lobular carcinoma showed suspicious morphology, there are limited kinetic indications of
malignancy
(a) First postcontrast T1 image, with a DICOM stamp showing a time of 202 seconds after
precontrast image.
(b) Figure 4a overlaid with map showing positive morphologic blooming (red) and near-
positive morphologic blooming (yellow).
(c) Figure 4a with a kinetic map overlay showing no significant areas of washout (red) plateau
(yellow).
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Fig 5. A 53-year-old female imaged on Siemens Magnetom system. Patient had two areas identified
on magnetic resonance as suspicious. Both areas were found to be ductal carcinoma in situ Grades
II-III on biopsy. The two regions identified as having suspicious morphologies match the regions
with positive biopsies. Only the inferior lesion had suspicious kinetics
(a) First postcontrast T1 image, with a DICOM stamp showing a time of 904 seconds after
precontrast image.
(b) Figure 5a overlaid with map showing suspicious morphologic blooming.
(c) Figure 5a with a kinetic map overlay showing no significant areas of washout (red) and a
very small area of plateau (yellow) in anterior-inferior region.
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Table 1
Systems and protocols used by institutions in multi-center study (Testing Data)
Institution 1 Institution 2 Institution 3 Institution 4 Institution 5
MRI System Siemens Sonata Philips Intera Siemens
Magnetom
GE LX GE Signa
Sequence Spoiled gradient-echo Gradient echo
with Sense
software
Gradient echo FSPGR FSPGR
Bilateral/Unilateral Bilateral
Interleaved











Yes No: 8 C/3 NC.
Yes: 16C/1 NC
Yes Yes Yes
Matrix 256x256 and 512x512 179x256 256x256 256x292 256x256
cancerous (C) breasts 5 24 4 28 10
non-
cancerous (NC) breasts
43 4 8 43 10
Basis of assessment of
non-cancerous
No suspicious findings






















Data from DICOM headers: Minimum-Maximum (Mean)
Interval between time of
pre-contrast and time of
post-contrast image used
in study (sec)
115–317 (220) 157–534 (318) 241–904 (588) 170–784 (374) 373–
1713 (943)
Echo time (msec) 1.8 – 6.5 (4.5) 5.9 – 6.5 (6.3) 4.5 – 4.5 (4.5) 2.3 – 5.0 (2.8) 1.8 – 2.4 (2.1)
Repetition time (msec) 7.7 – 26.0 (11.8) 32.9 – 33.0
(32.9)




Flip angle (deg) 25 – 30 (35.4) 55 – 55 (55.0) 35 – 40 (35.4) 35 – 45 (37.0) 35 – 35 (35.0)
Slice Thickness (mm) 2.2 – 4.2 (2.9) 3.0 – 4.4 (3.9)
with 2 mm
overlap
2.2 – 3.0 (2.9) 1.0 – 4.0 (3.0) 2.0 – 3.0 (2.9)
FOV (mm) 18 – 22 (20.0) 20 – 22 (20.2) 20 – 20 (20.0) 18 – 24 (20.3) 18 – 22 (19.6)
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Table 2
FP rates in non-cancerous breasts for patients with/without cancer in contralateral breast
Cancer absent in contralateral breast Cancer present in contralateral breast
Number breasts Mean FP/breast Number breasts Mean FP/breast
Institution 1 38 0.34 5 0.80
Institution 4 4 1.00 25 5.96
All 5 Institutions 42 0.48 38 4.29
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Table 3
Definitions and statistics used in the analysis of Morphological Blooming and kinetics as complementary methods
for detecting breast cancer
Morphological Blooming Kinetics Morphological Blooming
plus Kinetics
How evaluated Computer analysis Reader Interpretations
Criteria for positive finding Blooming value ≥10 Median finding of “plateau” or
“washout”
Positive finding using either
method
Sensitivity 78% 67% 89%
False negatives 10/45 15/45 5/45
Sensitivity on set of false negatives
from complementary method
10/15 (67%) 5/10 (50%)
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